Health Canada
www.hc-sc.gc.ca
Common menu bar links
MIRENA (Levonorgestrel-Releasing Intrauterine System) - Potential Risk of Uterine Perforation - For the Public
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
(PDF Version - 278 K)Contact: Marketed Health Products Directorate
The Health Products and Food Branch (HPFB) posts on the Health Canada Web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.
This is duplicated text of a letter from Bayer Inc.
Contact the company for a copy of any references, attachments or enclosures.
Public Communication
Health Canada Endorsed Important Safety Information on MIRENA
June 15, 2010
Subject: Association of MIRENA® (Levonorgestrel-releasing Intrauterine System) with the potential risk of uterine perforation
Bayer Inc., in collaboration with Health Canada, wishes to inform about important safety information regarding reports of uterine perforation in women treated with MIRENA®.
MIRENA®, a therapeutic intrauterine system, is authorized in Canada for prevention of pregnancy and treatment of heavy menstrual bleeding. Uterine perforation is a rare complication associated with all intrauterine contraceptive devices/systems, including MIRENA®. Perforation occurs at a rate between 1/1,000 and 1/10,000 insertions. Bayer Inc. continues to receive reports of uterine perforation associated with the use of MIRENA®. The risk of perforation may be increased after pregnancy, during lactation, and in women with atypical uterine anatomy. Uterine perforation may occur as MIRENA® is being inserted or after the insertion with limited symptoms. In order to reduce the risk of uterine perforation and associated complications, you should consider the following recommendations:
- Ask your doctor if MIRENA® is right for you.
- Tell your doctor the timing of your last pregnancy and whether you are currently breastfeeding.
- Ask your doctor on how to identify possible signs of uterine perforation. This may include, but is not limited to severe lower abdominal pain which may be accompanied with bleeding. Ask your doctor how you can check that the removal threads of MIRENA® are still in place.
- Re-visit your doctor within 4 to 12 weeks after insertion, and once-a-year thereafter.
MIRENA® works by slowly releasing levonorgestrel directly into the uterus to prevent pregnancy and to treat heavy menstrual bleeding. Levonorgestrel is a hormone commonly used in combination oral contraceptives.
Bayer Inc., in collaboration with Health Canada, issued a letter to Canadian Health Care Professionals reminding them of this important safety information which is part of the current MIRENA® Product Monograph. A copy of that letter is available on the Health Canada web site.
For more information about MIRENA®, patients should consult
their doctor or refer to the patient information document available
on the 
Bayer
Web site.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of uterine perforation or other serious or unexpected adverse reactions in patients receiving MIRENA® should be reported to Bayer Inc. or Health Canada at the following addresses:
77 Belfield Road
Toronto, Ontario,
M9W 1G6
Toll-free telephone: 1-800-265-7382;
Email to: Canada.medinfo@bayer.com
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701E
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
CanadaVigilance@hc-sc.gc.ca
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 1-866-234-2345
Fax: 1-866-678-6789
Postage paid labels, the Canada Vigilance Reporting Forms and the
Adverse Reaction Reporting Guidelines can be found on the MedEffectTM Canada Web site in the Adverse
Reaction Reporting section. The Reporting Form is
also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (industry).
Sincerely,
original signed by
Shurjeel Choudhri, MD FRCPC
Senior Vice President & Head, Medical & Scientific
Affairs
Bayer HealthCare Pharmaceuticals
Reference:
1. MIRENA Product Monograph, May 11, 2010.
